MX2021011575A - Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. - Google Patents

Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.

Info

Publication number
MX2021011575A
MX2021011575A MX2021011575A MX2021011575A MX2021011575A MX 2021011575 A MX2021011575 A MX 2021011575A MX 2021011575 A MX2021011575 A MX 2021011575A MX 2021011575 A MX2021011575 A MX 2021011575A MX 2021011575 A MX2021011575 A MX 2021011575A
Authority
MX
Mexico
Prior art keywords
sup
treatment
pharmaceutical compositions
compounds
new compounds
Prior art date
Application number
MX2021011575A
Other languages
English (en)
Spanish (es)
Inventor
Gregory John Robert Newsome
Reginald Christophe Xavier Brys
Oscar Mammoliti
Marielle Gilles Babel
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2021011575A publication Critical patent/MX2021011575A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021011575A 2019-03-29 2020-03-24 Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. MX2021011575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1904374.4A GB201904374D0 (en) 2019-03-29 2019-03-29 Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
PCT/EP2020/058063 WO2020200899A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
MX2021011575A true MX2021011575A (es) 2021-10-13

Family

ID=66443107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011575A MX2021011575A (es) 2019-03-29 2020-03-24 Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.

Country Status (14)

Country Link
US (1) US20220194938A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947377A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022526176A (cg-RX-API-DMAC7.html)
KR (1) KR20210143904A (cg-RX-API-DMAC7.html)
CN (1) CN113677679A (cg-RX-API-DMAC7.html)
AU (1) AU2020254882A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019110A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134735A1 (cg-RX-API-DMAC7.html)
GB (1) GB201904374D0 (cg-RX-API-DMAC7.html)
IL (1) IL286685A (cg-RX-API-DMAC7.html)
MX (1) MX2021011575A (cg-RX-API-DMAC7.html)
PH (1) PH12021552376A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110678UA (cg-RX-API-DMAC7.html)
WO (1) WO2020200899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
US7566781B2 (en) * 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
CA2992406A1 (en) * 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
WO2017207386A1 (de) * 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
KR20210143904A (ko) 2021-11-29
BR112021019110A2 (pt) 2021-11-30
AU2020254882A1 (en) 2021-11-25
CN113677679A (zh) 2021-11-19
CA3134735A1 (en) 2020-10-08
PH12021552376A1 (en) 2022-09-19
JP2022526176A (ja) 2022-05-23
IL286685A (en) 2021-10-31
US20220194938A1 (en) 2022-06-23
GB201904374D0 (en) 2019-05-15
WO2020200899A1 (en) 2020-10-08
SG11202110678UA (en) 2021-10-28
EP3947377A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
EA202091512A1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
PH12021552375A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2020003863A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
PH12021552377A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2020010805A (es) Inhibidores de bcl6.
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
EP3649119A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2024010344A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
PH12021552376A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
EA202192057A1 (ru) Карбаматные производные и их применение